RESEARCH INTERESTS

Developmental Biology

Small molecules are powerful tools for studying developmental biology because they provide timing and dosage control over developmental pathways that is difficult to achieve with genetic mutations. Unfortunately, only a handful of developmental pathways can currently be targeted with small molecules. We are discovering novel chemical modifiers of developmental pathways by exposing zebrafish embryos to libraries of structurally diverse small molecules and identifying those that induce specific developmental defects. Using screens of this type, we have discovered dozens of compounds that cause specific defects in hematopoesis, cardiac physiology, embryonic patterning, pigmentation, and morphogenesis of the heart, brain, ear, and eye and germ cell lineage.

Disease Physiology

One focus of our group is modeling human diseases in zebrafish. We then use the models to screen large chemical libraries for small molecule modulators of the disease-related phenotypes. The compounds we discover help us elucidate disease mechanisms and serve as starting points for developing new drug candidates.

Disease physiology is often complex and involves interactions between multiple organs and tissue types. Consequently, many diseases cannot be studied effectively using in vitro assays. The zebrafish is an excellent vertebrate model system to study many complex, non-cell autonomous diseases because the diseases can be studied in a native, whole-organism setting. In addition, compounds discovered in zebrafish screens have the advantage of having been selected for their ability to be active, efficacious, and well tolerated in animals.

Neuroscience & Behavior

Behaviors are accessible readouts of the molecular pathways that control neuronal signaling. Our group develops tools and techniques for comprehensive and high-throughput behavioral phenotyping in the zebrafish. These tools have some potential to improve our understanding of the neuronal signlaing and may accelerate the pace of neuroactive drug discovery.

Zebrafish Reverse Genetics

Zebrafish have proven to be a powerful genetic tool over the years, primarily through forward genetic screens where fish are mutagenized (typically with chemical agent) and screened for obvious defects. We are now on the verge of the next exciting step in zebrafish genetics: reverse genetics! Using targeted DNA disruption, we are now making designer mutations in specific genes of interest. Here are some of the resent papers describing three different processes.

GRANTS

  • EXTERNAL GRANT OR CONTRACT
    THE ROLE OF REDOX BALANCE IN CYANIDE TOXICITY AND MITOCHONDRIAL DISEASE
    NIH NATL INST NEUROLOG DISORDERS STROKE1 Sep 2024 - 30 Aug 2025
    NIH NATL INST NEUROLOG DISORDERS STROKE
  • EXTERNAL GRANT OR CONTRACT
    MULTIMODAL PHENOTYPING OF ZEBRAFISH MODELS OF HUMAN DISEASE
    15 Jun 2024 - 31 May 2028
  • EXTERNAL GRANT OR CONTRACT
    THE ROLE OF REDOX BALANCE IN CYANIDE TOXICITY AND MITOCHONDRIAL DISEASE
    NIH NATL INST NEUROLOG DISORDERS STROKE1 Sep 2023 - 31 Aug 2024
    NIH NATL INST NEUROLOG DISORDERS STROKE
  • EXTERNAL GRANT OR CONTRACT
    ADVANCING GENE-EDITING NUCLEASES FOR DIVERSE ZEBRAFISH APPLICATIONS
    3 Jun 2023 - 31 Aug 2027
  • EXTERNAL GRANT OR CONTRACT
    ADVANCING GLYOXYLATE AS A CHEMICAL COUNTERMEASURE (PROJECT 2)
    BRIGHAM & WOMENS HOSPITAL1 Jun 2023 - 31 May 2025
    BRIGHAM & WOMENS HOSPITAL
  • EXTERNAL GRANT OR CONTRACT
    ADVANCING NOVEL CYANIDE COUNTERMEASURES
    BRIGHAM & WOMENS HOSPITAL1 Jun 2023 - 31 May 2025
    BRIGHAM & WOMENS HOSPITAL
  • EXTERNAL GRANT OR CONTRACT
    IN VIVO FUNCTIONAL SCREEN OF NONCODING GENETIC ELEMENTS
    2 Sep 2022 - 31 Jan 2024
  • EXTERNAL GRANT OR CONTRACT
    THE ROLE OF REDOX BALANCE IN CYANIDE TOXICITY AND MITOCHONDRIAL DISEASE
    1 Sep 2022 - 31 Aug 2023
  • EXTERNAL GRANT OR CONTRACT
    ADVANCING GENE-EDITING NUCLEASES FOR DIVERSE ZEBRAFISH APPLICATIONS
    20 Sep 2019 - 31 Aug 2023
  • EXTERNAL GRANT OR CONTRACT
    PENNY'S K99/R00
    NIH NATL INST NEUROLOG DISORDE9 Jan 2019 - 31 Dec 2020
    NIH NATL INST NEUROLOG DISORDE
  • EXTERNAL GRANT OR CONTRACT
    BWH PROJECT 2
    BRIGHAM & WOMENS HOSPITAL8 Jan 2019 - 31 Dec 2022
    BRIGHAM & WOMENS HOSPITAL
  • EXTERNAL GRANT OR CONTRACT
    TRAINING & EDUCATION CORE
    BRIGHAM & WOMENS HOSPITAL8 Jan 2019 - 31 Dec 2022
    BRIGHAM & WOMENS HOSPITAL
  • EXTERNAL GRANT OR CONTRACT
    PETERSON - GATES
    BILL & MELINDA GATES FOUNDATIO5 Jan 2017 - 31 Dec 2018
    BILL & MELINDA GATES FOUNDATIO
  • EXTERNAL GRANT OR CONTRACT
    PETERSON - SUB - LONG QT
    MASSACHUSETTS GENERAL HOSPITAL4 Jan 2017 - 31 Dec 2020
    MASSACHUSETTS GENERAL HOSPITAL
  • FELLOWSHIP OR RESIDENCY
    AHA FELLOWSHIP FOR PENNY LAM
    AMERICAN HEART ASSOCIATION1 Jan 2017 - 31 Dec 2018
    AMERICAN HEART ASSOCIATION
  • EXTERNAL GRANT OR CONTRACT
    CORE B U54 MGH114930
    BRIGHAM & WOMENS HOSPITAL1 Jan 2017 - 31 Dec 2018
    BRIGHAM & WOMENS HOSPITAL
  • EXTERNAL GRANT OR CONTRACT
    NLGN3 AND TRANSLATION
    HOFFMAN-LA ROCHE INC1 Jan 2017 - 11 Dec 2017
    HOFFMAN-LA ROCHE INC
  • EXTERNAL GRANT OR CONTRACT
    PETERSON SUB - BLOCH
    MASSACHUSETTS GENERAL HOSPITAL1 Jan 2017 - 31 Dec 2019
    MASSACHUSETTS GENERAL HOSPITAL
  • EXTERNAL GRANT OR CONTRACT
    PROJECT 2 U54 MGH114928
    BRIGHAM & WOMENS HOSPITAL1 Jan 2017 - 31 Dec 2018
    BRIGHAM & WOMENS HOSPITAL
  • EXTERNAL GRANT OR CONTRACT
    TEJIA ZHANG
    MASSACHUSETTS GENERAL HOSPITAL1 Jan 2017 - 31 Dec 2017
    MASSACHUSETTS GENERAL HOSPITAL
  • EXTERNAL GRANT OR CONTRACT
    TRAINEES
    MASSACHUSETTS GENERAL HOSPITAL1 Jan 2017 - 31 Dec 2017
    MASSACHUSETTS GENERAL HOSPITAL
  • EXTERNAL GRANT OR CONTRACT
    ZEBRAFISH HEART FAILURE
    MERCK SHARP & DOHME LLC1 Jan 2017 - 31 Dec 2019
    MERCK SHARP & DOHME LLC